Bolt Biotherapeutics (BOLT) Investor Presentation - Slideshow

Biomarkers Consistent with Mechanism • Increases myeloid & T cell frequency in tumor • Minimal systemic inflammatory effect in plasma Early Signs of Clinical Disease Control • Early signs of disease control, below target exposure level • Durable disease control (SD or PR) noted in 13/40 evaluable subjects Dose Escalation Nearing Completion • Anticipate achieving threshold exposure with more frequent dosing • Monotherapy and Opdivo combination enrollment complete 7 Opdivo® is a trademark of Bristol-Myers Squ ...